[Role of neutralizing anti-interferon antibodies during interferon therapy in patients with chronic hepatitis B].
OBJECTIVE
Investigation in the role of neutralizing anti-interferon antibodies(NA) during interferon therapy in patients with chronic hepatitis B.


METHODS
To measure the levels of NA in 48 patients with chronic hepatitis B (CHB) treated with interferon-alpha (IFN-alpha) at the point before treated and at 3 and 6 months with treatment respectively. At the same time to measure the levels of NA in health volunteers.


RESULTS
NA can not be measured in health volunteers and those patients with CHB at the point before treated. At the point of 6 months with treatment, 15 patients with CHB got complete respond, 10 patients with CHB got no respond, 23 patients with CHB got partly respond, respectively. NA positive rate was 25% at 3 months and 37.5% at 6 months with treatment, respectively. (P > 0.05). NA positive rate was significantly higher in complete responders group and partly responders group than in no responders group at 3 months with. NA positive rate was significantly higher in complete responders group than in no responders group at 3 months with.


CONCLUSIONS
NA can be measured in blood serum after treated with interferon. NA influences the efficacy of interferon, especially at 3 months.
Wang
Yong-Ping
YP
The Fifth People's Hospital of Suzhou 215007, China.
D000328:Adult; D057134:Antibodies, Neutralizing / Q000097:blood*; D004334:Drug Administration Schedule; D005260:Female; D019694:Hepatitis B, Chronic / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
D057134:Antibodies, Neutralizing; D016898:Interferon-alpha